Lista de obras - Irina Isakova-Sivak - Dominio Público Uruguay

A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults

artículo científico publicado en 2020

Analysis of Immune Epitopes of Respiratory Syncytial Virus for Designing of Vectored Vaccines Based on Influenza Virus Platform.

artículo científico publicado en 2016

Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.

artículo científico publicado en 2014

Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.

artículo científico publicado en 2015

Basics of CD8 T-cell immune responses after influenza infection and vaccination with inactivated or live attenuated influenza vaccine

article

Broadly protective anti-hemagglutinin stalk antibodies induced by live attenuated influenza vaccine expressing chimeric hemagglutinin.

artículo científico publicado en 2018

Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.

artículo científico publicado en 2014

Cold-adapted influenza viruses as a promising platform for viral-vector vaccines.

artículo científico publicado en 2016

Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets

artículo científico publicado en 2011

Comparative studies of infectivity, immunogenicity and cross-protective efficacy of live attenuated influenza vaccines containing nucleoprotein from cold-adapted or wild-type influenza virus in a mouse model

artículo científico publicado en 2016

Contribution of neuraminidase of influenza viruses to the sensitivity to sera inhibitors and reassortment efficiency

artículo científico publicado en 2014

Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine

artículo científico publicado en 2014

Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.

artículo científico publicado en 2016

Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.

artículo científico publicado en 2014

Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2).

artículo científico publicado en 2011

Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.

artículo científico publicado en 2015

Genotyping assay for differentiation of wild-type and vaccine viruses in subjects immunized with live attenuated influenza vaccine

artículo científico publicado en 2017

H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers.

artículo científico publicado en 2015

H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus

artículo científico publicado en 2013

H7N9 Live Attenuated Influenza Vaccine Is Highly Immunogenic, Prevents Virus Replication, and Protects Against Severe Bronchopneumonia in Ferrets

artículo científico publicado en 2016

H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial.

artículo científico publicado en 2015

H7N9: can H7N3 live-attenuated influenza vaccine be used at the early stage of the pandemic?

artículo científico publicado en 2013

Immunogenicity and Cross Protection in Mice Afforded by Pandemic H1N1 Live Attenuated Influenza Vaccine Containing Wild-Type Nucleoprotein.

artículo científico publicado en 2017

Insights into current clinical research on the immunogenicity of live attenuated influenza vaccines

artículo científico publicado en 2020

Live Attenuated Influenza Vaccines engineered to express the nucleoprotein of a recent isolate stimulate human influenza CD8+ T cells more relevant to current infections

artículo científico publicado en 2017

Live attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage site

article

M2e-based universal influenza vaccines: a historical overview and new approaches to development

artículo científico publicado en 2019

Overview of human rhinovirus immunogenic epitopes for rational vaccine design

scientific article published on 21 August 2019

Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus

artículo científico publicado en 2015

Reassortant viruses for influenza vaccines: is it time to reconsider their genome structures?

artículo científico publicado en 2016

Recombinant Live Attenuated Influenza Vaccine Viruses Carrying Conserved T-cell Epitopes of Human Adenoviruses Induce Functional Cytotoxic T-Cell Responses and Protect Mice against Both Infections

scientific article published on 24 April 2020

Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease

scientific article published on 07 May 2019

Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.

artículo científico publicado en 2015

Sequential Immunization with Universal Live Attenuated Influenza Vaccine Candidates Protects Ferrets against a High-Dose Heterologous Virus Challenge

scientific article published on 08 July 2019

Tackling a novel lethal virus: a focus on H7N9 vaccine development.

artículo científico publicado en 2017

The development of vaccine viruses against pandemic A(H1N1) influenza ⬇️

artículo científico publicado el 17 de febrero de 2011

Two Live Attenuated Vaccines against Recent Low⁻and Highly Pathogenic H7N9 Influenza Viruses Are Safe and Immunogenic in Ferrets

scientific article published on 01 November 2018

Use of live attenuated influenza vaccines in young children in resource-poor settings

artículo científico publicado en 2016

Lista de obras de Irina Isakova-Sivak

A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults

Analysis of Immune Epitopes of Respiratory Syncytial Virus for Designing of Vectored Vaccines Based on Influenza Virus Platform.

Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.

Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.

Basics of CD8 T-cell immune responses after influenza infection and vaccination with inactivated or live attenuated influenza vaccine

Broadly protective anti-hemagglutinin stalk antibodies induced by live attenuated influenza vaccine expressing chimeric hemagglutinin.

Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.

Cold-adapted influenza viruses as a promising platform for viral-vector vaccines.

Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets

Comparative studies of infectivity, immunogenicity and cross-protective efficacy of live attenuated influenza vaccines containing nucleoprotein from cold-adapted or wild-type influenza virus in a mouse model

Contribution of neuraminidase of influenza viruses to the sensitivity to sera inhibitors and reassortment efficiency

Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine

Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.

Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.

Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2).

Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.

Genotyping assay for differentiation of wild-type and vaccine viruses in subjects immunized with live attenuated influenza vaccine

H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers.

H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus

H7N9 Live Attenuated Influenza Vaccine Is Highly Immunogenic, Prevents Virus Replication, and Protects Against Severe Bronchopneumonia in Ferrets

H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial.

H7N9: can H7N3 live-attenuated influenza vaccine be used at the early stage of the pandemic?

Immunogenicity and Cross Protection in Mice Afforded by Pandemic H1N1 Live Attenuated Influenza Vaccine Containing Wild-Type Nucleoprotein.

Insights into current clinical research on the immunogenicity of live attenuated influenza vaccines

Live Attenuated Influenza Vaccines engineered to express the nucleoprotein of a recent isolate stimulate human influenza CD8+ T cells more relevant to current infections

Live attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage site

M2e-based universal influenza vaccines: a historical overview and new approaches to development

Overview of human rhinovirus immunogenic epitopes for rational vaccine design

Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus

Reassortant viruses for influenza vaccines: is it time to reconsider their genome structures?

Recombinant Live Attenuated Influenza Vaccine Viruses Carrying Conserved T-cell Epitopes of Human Adenoviruses Induce Functional Cytotoxic T-Cell Responses and Protect Mice against Both Infections

Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease

Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.

Sequential Immunization with Universal Live Attenuated Influenza Vaccine Candidates Protects Ferrets against a High-Dose Heterologous Virus Challenge

Tackling a novel lethal virus: a focus on H7N9 vaccine development.

The development of vaccine viruses against pandemic A(H1N1) influenza ⬇️

Two Live Attenuated Vaccines against Recent Low⁻and Highly Pathogenic H7N9 Influenza Viruses Are Safe and Immunogenic in Ferrets

Use of live attenuated influenza vaccines in young children in resource-poor settings